Mitsubishi Tanabe Pharma has deployed ArisGlobal's new pharmacovigilance and clinical safety solutions including ARISg and ARISj.
ARISg and ARISj solutions are designed for collecting, assessing, distributing and managing adverse event reporting requirements of different authorities from case entry to automatic generation of submission-ready adverse event reports.
The new solutions will enable Mitsubishi to meet safety reporting needs at its headquarters in Japan, as well as its affiliates in the US and Europe, with ease-of-use and increased business efficiency.
The solutions will also enable Mitsubishi to unify and streamline the management of safety information by consolidating multiple safety systems into one.
ArisGlobal president and CEO Deepak Abbhi said the advanced functionalities and architecture of the company's solution allows its customers to meet the complex and rigorous safety reporting demands of regulatory agencies across the world including the PMDA here in Japan.
"The combination of ARISg and ARISj will provide Mitsubishi Tanabe Pharma Corporation with an efficient mechanism for sharing safety data while ensuring compliance across all regions," Abbhi added.